MannKind develops and sells inhaled and wearable treatments for diabetes, heart failure and lung conditions. It last closed at $4.07 on Nov 17, up 2.91% on the day. The average 12-month price target from 4 analysts is $7.50 (+84.3% from the last close), with a high of $10.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell).
Each firm's latest rating on MNKD in the past 90 days
Average 12-month target
$7.50
▲ 84.3% upside
Based on 4 analysts who set a price target on MNKD in the past 90 days. The average target is $7.50, with a high of $10.00 and a low of $5.00, compared with the last close of $4.07.
Highest target$10.00
Average target$7.50
Lowest target$5.00
Latest rating changes
RBC CapitalTarget raised
Nov 6Hold$3.50 → $5
Cantor FitzgeraldTarget raised
Nov 6Buy$6.50 → $10
Chardan CapitalInitiated
Oct 19Buy$10
Truist SecuritiesMaintained
Oct 7Buy$5
Cantor FitzgeraldReiterated
Sep 11Buy$6.50
Date
Firm
Action
Rating
Price target
Nov 6
RBC Capital
Target raised
Hold
$3.50 → $5
Nov 6
Cantor Fitzgerald
Target raised
Buy
$6.50 → $10
Oct 19
Chardan Capital
Initiated
Buy
$10
Oct 7
Truist Securities
Maintained
Buy
$5
Sep 11
Cantor Fitzgerald
Reiterated
Buy
$6.50
Loading…
Technical Analysis
MNKD · as of the Nov 17 close · updated after every close
Turning up
The stock is 9% above its 20 day and 12% above its 50 day average. It is 11% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62). The nearest support is the Pivot at $4.05, and the nearest resistance the swing high (Jul 31) at $4.14.
Short trendBullish
Long trendNeutral
MomentumStrong
StretchNormal
VolatilityNormal, 5.0%/day
Key levels
$6.5152 week high+60.0%
$4.20Pivot R1+3.2%
$4.14Swing high (Jul 31)+1.7%
$4.07Last close
$4.05Pivot−0.5%
$3.92Pivot S1−3.7%
$3.90Swing low (Aug 31)−4.2%
$3.80100 day average−6.6%
$3.7120 day average−8.8%
$3.63200 day average−10.8%
$3.5750 day average−12.3%
$2.2352 week low−45.2%
Indicators
RSI (14)
61.73
Strong, overbought above 70
Neutral
MACD
0.19
Above its signal line
Bullish
Stochastic
76.3
Middle of its range
Neutral
ADX (14)
26.9
Trending up
Williams %R
-25.8
Oversold below −80, overbought above −20
Neutral
CCI (20)
67.2
Oversold below −100, overbought above 100
Neutral
Rate of change
+9.1%
Change over 10 sessions
Bullish
ATR (14)
$0.20
Typical daily range, 5.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Bounce inside a longer downtrend
Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 11.7%/day
Key levels
$6.5152 week high+60.0%
$4.20Pivot R1+3.2%
$4.14Swing high (Jul 31)+1.7%
$4.07Last close
$4.05Pivot−0.5%
$3.92Pivot S1−3.7%
$3.90Swing low (Aug 31)−4.2%
$3.80100 day average−6.6%
$3.7120 day average−8.8%
$3.63200 day average−10.8%
$3.5750 day average−12.3%
$2.2352 week low−45.2%
Indicators
RSI (14)
54.21
Middle of its range
Neutral
MACD
-0.03
Above its signal line
Bullish
Stochastic
75.4
Middle of its range
Neutral
ADX (14)
21.1
Weak trend
Williams %R
-22.0
Oversold below −80, overbought above −20
Neutral
CCI (20)
59.8
Oversold below −100, overbought above 100
Neutral
Rate of change
+8.5%
Change over 10 sessions
Bullish
ATR (14)
$0.48
Typical daily range, 11.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for MNKD
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MNKD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow MNKD usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MNKD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNKD is in one of them and how their past MNKD trades turned out.
MannKind is a biopharmaceutical company based in Danbury, Connecticut. Its products include Afrezza, an inhaled mealtime insulin for adults with diabetes, V-Go, a wearable insulin delivery device, and Furoscix, a home-use treatment for fluid buildup linked to heart failure and chronic kidney disease. Its Tyvaso DPI treatment for pulmonary hypertension is sold by partner United Therapeutics, which pays MannKind royalties. The company makes its inhalable powders and inhalers at its Connecticut facility and sells Afrezza in the United States and through partners in other countries.